Treatment of melanoma, the choice of targeted therapy or immunotherapy
November 15, 2016 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Researchers from McMaster University in Canada recently found that for advanced melanoma patients, the combination of several immunotherapeutic methods can improve patient survival and reduce the risk of life-threatening events.
“This is the first analytical study to compare targeted therapy and immunotherapy for the treatment of BRAF mutant melanoma,†said Associate Professor Feng Xie. “Our results will help patients and doctors choose the best treatment.â€
Feng Xie is an independent researcher who led the research and published the results in the international academic journal JAMA Oncology.
Melanoma is a deadly skin cancer that is highly aggressive. According to the Canadian Cancer Society, about 3.3% of new cancer cases in Canada each year are melanoma. In the early stages of melanoma, surgery can be achieved only by surgery, but most patients in the advanced stage of cancer are not suitable for surgery, and drug treatment is the main treatment.
The researchers say that about 40% to 60% of melanomas have BRAF protein mutations.
Therapeutic methods for patients with advanced BRAF mutant melanoma are mainly classified into two categories: targeted therapy, such as chemotherapy, which can prevent cancer from growing and spreading; and immunotherapy, which stimulates the immune system to attack tumor cells. But what is the best initial treatment is still unclear.
The aim of this study was to evaluate the efficacy and safety of different systemic therapies for patients diagnosed with advanced BRAF mutant melanoma but who have not received any treatment.
The researchers analyzed data from 15 randomized controlled trials published between 2011 and 2015, including a total of 6662 cancer patients who had cancer cells that had spread to the lymph nodes and were not suitable for surgery, or that melanoma had already occurred. End transfer. The researchers evaluated the benefits and disadvantages of targeted therapy or immunological checkpoint inhibitors for these patients.
They found that BRAF and MEK combined with targeted therapy and PD-1 immunotherapy are equally effective in improving overall survival. Combined inhibition of BRAF and MEK is most effective in increasing progression-free survival. PD-1 inhibitors are associated with a significant reduction in the risk of life-threatening events.
The researchers concluded that the safety of PD-1 inhibitor drugs supports the treatment as a first-line treatment option without the need for rapid treatment.
"The data provided by our study provides good evidence that the use of more than one immunotherapeutic drug demonstrates hope in the early results of clinical trials, and once long-term findings are published, this strategy will change the patient's treatment plan." Feng Xie said this.
Hydrogel Dressing,Hydrogel For Wounds,Hydrogel Wound Gel,Hydrogel Sheet Wound Dressing
Roosin Medical Co.,Ltd , https://www.roosinmedical.com